Olema Pharmaceuticals, Inc. (OLMA) · Oct 15, 2026 · Exec change
Director resignation — Resignation effective October 14; committees reassigned October 15
Olema Pharmaceuticals disclosed a board resignation and immediate committee reassignment, with no stated operational disagreement or pipeline change.
Olema is a clinical-stage oncology company advancing palazestrant through pivotal Phase 3 breast-cancer trials while developing the earlier-stage OP-3136 program.
This is a governance reshuffle, not a change to the drug-development story. Dr. Gorjan Hrustanovic resigned from the board effective October 14 and left the Compensation and Science and Technology committees; the filing explicitly says the resignation was not due to a disagreement with the company. 〔0〕
Committee continuity is preserved. The board appointed Dr. Prakash Raman to both committees effective October 15, limiting the practical disruption to a seat change rather than a loss of oversight. 〔1〕
Bottom line: This is a routine executive-governance change with no disclosed impact on Olema’s clinical programs, strategy, or operating plans. It matters far less than the upcoming palazestrant data readouts that drive the company’s business story.
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!